Oramed phase 2 insulin drug data ‘paint an exciting picture’ in rocky NASH landscape
Oramed Pharmaceuticals has posted encouraging phase 2 results for its oral insulin candidate designed to treat diabetes and non-alcoholic steatohepatitis (NASH). The company now awaits phase 3 readouts for the candidate that holds potential to become the first commercial oral insulin capsule for treating diabetes.